流行病诊疗板块多股扬升 雅培(ABT)涨1.60%、强生(JNJ)涨1.12%

金吾财讯
May 12

金吾财讯 | 汉坦病毒疫情叠加药企药物研发/合作进展向好消息提振,美股流行病诊疗板块多股扬升,截至发稿,葛兰素史克 (GSK) 涨 1.93%,雅培 (ABT) 涨 1.60%,默沙东 (MRK) 涨 1.41%,阿斯利康 (AZN) 涨 1.18%,强生 (JNJ) 涨 1.12%。消息面上,强生周二宣布其Shockwave C2 Aero冠状动脉IVL导管于全球上市,该导管旨在提高输送性、增强病变通过能力并具备新的重定位功能,用于治疗钙化冠状动脉疾病(CAD)。这一新一代冠状动脉IVL导管利用了Shockwave IVL的独特作用机制及其传统导管的安全性和有效性特点,扩展了该公司市场领先的IVL产品组合。中国生物制药集团附属公司正大天晴药业集团股份有限公司与葛兰素史克(“GSK”)新近达成一项独家战略合作,加速bepirovirsen在中国内地的上市进程。根据协议条款,正大天晴将负责bepirovirsen在中国内地的进口、分销、医院准入以及推广和非推广活动,该产品产生的全部销售收入将确认为正大天晴的营业收入。GSK将继续作为药品上市许可持有人(MAH),负责监管注册事务、质量控制、药物警戒及全球医学策略等工作。达歌生物周二宣布与默沙东研发(中国)有限公司签署合作协议,共同推进抗肿瘤药物临床合作开发。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10